Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 16, 2017 - Issue 12
Submit an article Journal homepage
503
Views
6
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes

Baptist GallwitzDepartment of Medicine IV, Eberhard Karls University Tübingen, Tübingen, GermanyCorrespondence[email protected]
View further author information
Pages 1399-1405 | Received 12 Apr 2017, Accepted 12 Sep 2017, Published online: 11 Oct 2017

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

André J. Scheen. (2018) The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 17:8, pages 837-848.
Read now

Articles from other publishers (5)

Santenna Chenchula, Shoban Babu Varthya & R. Padmavathi. (2022) Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies. Current Diabetes Reviews 18:4.
Crossref
Matilda Florentin, Michael S Kostapanos & Athanasia K Papazafiropoulou. (2022) Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World Journal of Diabetes 13:2, pages 85-96.
Crossref
Baptist Gallwitz & Roland Schmieder. (2020) Metabolische Wirkungen und kardiovaskuläre Sicherheit einer oralen Dreifachtherapie des Typ-2-Diabetes: das Beispiel Metformin, Empagliflozin und Linagliptin. Diabetologie und Stoffwechsel 15:04, pages 317-326.
Crossref
Christopher Mackintosh, Arti Tewari, Jason Siegel, R. Doris Wang & William Freeman. (2019) Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and “Sweet Pee Encephalopathy” in Perioperative Hospital Management. The Neurohospitalist 10:1, pages 51-54.
Crossref
Annayya R. Aroor, Camila Manrique-Acevedo & Vincent G. DeMarco. (2018) The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovascular Diabetology 17:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.